Dec 9 (Reuters) - Achieve Life Sciences Inc ACHV.O :
* ANNOUNCES COMPLETION OF MEETING WITH THE U.S. FOOD & DRUG ADMINISTRATION (FDA) ON CYTISINICLINE SMOKING CESSATION PHASE 3 CLINICAL DEVELOPMENT PROGRAM
* PLANS TO INITIATE PHASE 3 DEVELOPMENT PROGRAM IN 2020, SUBJECT TO AVAILABILITY OF CAPITAL
* FDA AGREED USE OF NEWLY-DEVELOPED, SINGLE 3.0 MG CYTISINICLINE TABLET IN PHASE 3 PROGRAM WAS ACCEPTABLE
* FDA HAS AGREED WITH OVERALL PHASE 3 STUDY DESIGNS THAT WILL UTILIZE SIMPLIFIED CYTISINICLINE DOSING SCHEDULE
* CHRONIC TOXICOLOGY STUDY REPORT IS EXPECTED TO BE AVAILABLE AND SUBMITTED TO FDA IN Q1 OF 2020
* FDA AGREED NO FURTHER ESCALATION IN CYTISINICLINE DOSING BEYOND 30.0 MG DOSE WAS NECESSARY FOR DEFINING MAXIMUM TOLERATED DOSE